Santiago de Compostela, Spain – 5 September 2025 – Oncostellae, a clinical-stage biopharmaceutical company developing innovative therapies for inflammatory and immune-mediated diseases, today announced its participation in BIO-Europe 2025, taking place November 3–5, 2025, in Vienna, Austria.
BIO-Europe is one of Europe’s leading biopharmaceutical partnering events, bringing together biotechnology and pharmaceutical companies, investors and other life sciences stakeholders from around the world. The 2025 event in Vienna is expected to bring together more than 5,800 participants representing over 60 countries, with more than 32,000 one-to-one partnering meetings scheduled.
Oncostellae will participate in the one-to-one partnering program to present its pipeline and engage with potential pharmaceutical partners and investors. The company will place particular emphasis on OST-122, its lead clinical program for inflammatory bowel disease (IBD), and discuss opportunities for strategic collaboration and further development.
“BIO-Europe is an important opportunity for us to engage directly with pharmaceutical companies and investors as we advance OST-122 toward the next stage of clinical development,” said Guido Kurz, PhD, CEO of Oncostellae. “We look forward to presenting the progress of the program and exploring potential partnerships for the development and commercialization of OST-122.”Oncostellae is advancing OST-122, a gut-restricted JAK inhibitor designed to provide local therapeutic activity in the gastrointestinal tract while minimizing systemic exposure and associated safety liabilities, toward a Phase 2b clinical study in ulcerative colitis.
About Oncostellae
Oncostellae is a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies for diseases with significant unmet medical needs. The company’s lead program, OST-122, is a gut-restricted JAK inhibitor in development for inflammatory bowel disease, including ulcerative colitis.
